Literature DB >> 24334537

An efficient method for differentiation of human induced pluripotent stem cells into hepatocyte-like cells retaining drug metabolizing activity.

Yuki Kondo1, Takahiro Iwao, Katsunori Nakamura, Takamitsu Sasaki, Shogo Takahashi, Noboru Kamada, Tsutomu Matsubara, Frank J Gonzalez, Hidenori Akutsu, Yoshitaka Miyagawa, Hajime Okita, Nobutaka Kiyokawa, Masashi Toyoda, Akihiro Umezawa, Kiyoshi Nagata, Tamihide Matsunaga, Shigeru Ohmori.   

Abstract

The use of human induced pluripotent stem (iPS) cells would be of great value for a variety of applications involving drug development studies. Several reports have been published on the differentiation of human iPS cells into hepatocyte-like cells; however, the cells were insufficient for application in drug metabolism studies. In this study, we aimed to establish effective methods for differentiation of human iPS cells into hepatocytes. Two human iPS cell lines were differentiated by addition of activin A, dimethyl sulfoxide, hepatocyte growth factor, oncostatin M, and dexamethasone. The differentiated cells expressed hepatocyte markers and drug-metabolizing enzymes, revealing that the human iPS cells were differentiated into hepatocyte-like cells. Expression of CYP3A4 and UGT1A1 mRNAs increased with treatment with typical inducers of the enzymes, and the response of the cells against the inducers was similar to that of human hepatocytes. Furthermore, the drug-metabolizing activity of CYP3A4, as monitored by testosterone 6β-hydroxylase activity, was elevated by these inducers. In conclusion, we established methods for differentiation of hepatocyte-like cells expressing drug metabolizing activity from human iPS cells. The hepatocyte-like cells derived from human iPS cells will be useful for drug metabolism studies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24334537      PMCID: PMC6594155          DOI: 10.2133/dmpk.dmpk-13-rg-104

Source DB:  PubMed          Journal:  Drug Metab Pharmacokinet        ISSN: 1347-4367            Impact factor:   3.614


  46 in total

Review 1.  Fetal hepatic drug elimination.

Authors:  J A Ring; H Ghabrial; M S Ching; R A Smallwood; D J Morgan
Journal:  Pharmacol Ther       Date:  1999-12       Impact factor: 12.310

2.  Role for growth factors and extracellular matrix in controlling differentiation of prospectively isolated hepatic stem cells.

Authors:  Atsushi Suzuki; Atsushi Iwama; Hitoshi Miyashita; Hiromitsu Nakauchi; Hideki Taniguchi
Journal:  Development       Date:  2003-06       Impact factor: 6.868

3.  Fetal liver development requires a paracrine action of oncostatin M through the gp130 signal transducer.

Authors:  A Kamiya; T Kinoshita; Y Ito; T Matsui; Y Morikawa; E Senba; K Nakashima; T Taga; K Yoshida; T Kishimoto; A Miyajima
Journal:  EMBO J       Date:  1999-04-15       Impact factor: 11.598

4.  Oncostatin M and hepatocyte growth factor induce hepatic maturation via distinct signaling pathways.

Authors:  A Kamiya; T Kinoshita; A Miyajima
Journal:  FEBS Lett       Date:  2001-03-09       Impact factor: 4.124

5.  Differential drug-induced mRNA expression of human CYP3A4 compared to CYP3A5, CYP3A7 and CYP3A43.

Authors:  Solveigh Krusekopf; Ivar Roots; Ullrich Kleeberg
Journal:  Eur J Pharmacol       Date:  2003-04-11       Impact factor: 4.432

6.  Differential regulation of expression of hepatic and pulmonary cytochrome P4501A enzymes by 3-methylcholanthrene in mice lacking the CYP1A2 gene.

Authors:  Sudha R Kondraganti; Weiwu Jiang; Bhagavatula Moorthy
Journal:  J Pharmacol Exp Ther       Date:  2002-12       Impact factor: 4.030

Review 7.  Receptor-dependent transcriptional activation of cytochrome P4503A genes: induction mechanisms, species differences and interindividual variation in man.

Authors:  G G Gibson; N J Plant; K E Swales; A Ayrton; W El-Sankary
Journal:  Xenobiotica       Date:  2002-03       Impact factor: 1.908

8.  Maturation of fetal hepatocytes in vitro by extracellular matrices and oncostatin M: induction of tryptophan oxygenase.

Authors:  Akihide Kamiya; Nobuhiko Kojima; Taisei Kinoshita; Yasuyuki Sakai; Atsushi Miyaijma
Journal:  Hepatology       Date:  2002-06       Impact factor: 17.425

9.  Developmental expression of the major human hepatic CYP3A enzymes.

Authors:  Jeffrey C Stevens; Ronald N Hines; Chungang Gu; Sevasti B Koukouritaki; Jason R Manro; Peter J Tandler; Matthew J Zaya
Journal:  J Pharmacol Exp Ther       Date:  2003-09-15       Impact factor: 4.030

10.  Quantitative gene expression profiling reveals a fetal hepatic phenotype of murine ES-derived hepatocytes.

Authors:  Andrea Jochheim; Tina Hillemann; Gabriela Kania; Jennifer Scharf; Masoumeh Attaran; Michael P Manns; Anna M Wobus; Michael Ott
Journal:  Int J Dev Biol       Date:  2004-02       Impact factor: 2.203

View more
  10 in total

1.  Deterministically patterned biomimetic human iPSC-derived hepatic model via rapid 3D bioprinting.

Authors:  Xuanyi Ma; Xin Qu; Wei Zhu; Yi-Shuan Li; Suli Yuan; Hong Zhang; Justin Liu; Pengrui Wang; Cheuk Sun Edwin Lai; Fabian Zanella; Gen-Sheng Feng; Farah Sheikh; Shu Chien; Shaochen Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-08       Impact factor: 11.205

2.  H3K27me3 Does Not Orchestrate the Expression of Lineage-Specific Markers in hESC-Derived Hepatocytes In Vitro.

Authors:  Jolien Vanhove; Mariaelena Pistoni; Marc Welters; Kristel Eggermont; Veerle Vanslembrouck; Nicky Helsen; Ruben Boon; Mustapha Najimi; Etienne Sokal; Philippe Collas; J Willem Voncken; Catherine M Verfaillie
Journal:  Stem Cell Reports       Date:  2016-07-28       Impact factor: 7.765

3.  Hepatic differentiation of human iPSCs in different 3D models: A comparative study.

Authors:  Florian Meier; Nora Freyer; Joanna Brzeszczynska; Fanny Knöspel; Lyle Armstrong; Majlinda Lako; Selina Greuel; Georg Damm; Eva Ludwig-Schwellinger; Ulrich Deschl; James A Ross; Mario Beilmann; Katrin Zeilinger
Journal:  Int J Mol Med       Date:  2017-10-16       Impact factor: 4.101

Review 4.  Current Perspectives Regarding Stem Cell-Based Therapy for Liver Cirrhosis.

Authors:  Kyeong-Ah Kwak; Hyun-Jae Cho; Jin-Young Yang; Young-Seok Park
Journal:  Can J Gastroenterol Hepatol       Date:  2018-01-29

Review 5.  Induced pluripotent stem cells for therapy personalization in pediatric patients: Focus on drug-induced adverse events.

Authors:  Elena Genova; Federica Cavion; Marianna Lucafò; Luigina De Leo; Marco Pelin; Gabriele Stocco; Giuliana Decorti
Journal:  World J Stem Cells       Date:  2019-12-26       Impact factor: 5.326

6.  A fast screening model for drug permeability assessment based on native small intestinal extracellular matrix.

Authors:  Na Li; Zhigang Sui; Yong Liu; Dandan Wang; Guangbo Ge; Ling Yang
Journal:  RSC Adv       Date:  2018-10-08       Impact factor: 4.036

7.  Histone deacetylase inhibitor valproic acid promotes the differentiation of human induced pluripotent stem cells into hepatocyte-like cells.

Authors:  Yuki Kondo; Takahiro Iwao; Sachimi Yoshihashi; Kayo Mimori; Ruri Ogihara; Kiyoshi Nagata; Kouichi Kurose; Masayoshi Saito; Takuro Niwa; Takayoshi Suzuki; Naoki Miyata; Shigeru Ohmori; Katsunori Nakamura; Tamihide Matsunaga
Journal:  PLoS One       Date:  2014-08-01       Impact factor: 3.240

Review 8.  In Vitro Generated Hepatocyte-Like Cells: A Novel Tool in Regenerative Medicine and Drug Discovery.

Authors:  Kobra Zakikhan; Behshad Pournasr; Massoud Vosough; Marjan Nassiri-Asl
Journal:  Cell J       Date:  2017-02-22       Impact factor: 2.479

Review 9.  Controversies Surrounding the Origin of Hepatocytes in Adult Livers and the in Vitro Generation or Propagation of Hepatocytes.

Authors:  Nicole Min Qian Pek; Kevin J Liu; Massimo Nichane; Lay Teng Ang
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2020-09-28

10.  Adaptation of the in vitro micronucleus assay for genotoxicity testing using 3D liver models supporting longer-term exposure durations.

Authors:  Gillian E Conway; Ume-Kulsoom Shah; Samantha Llewellyn; Tereza Cervena; Stephen J Evans; Abdullah S Al Ali; Gareth J Jenkins; Martin J D Clift; Shareen H Doak
Journal:  Mutagenesis       Date:  2020-09-12       Impact factor: 3.000

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.